Disc Medicine (IRON) Director Bitterman Sells $879K of Stock
Key Points
- Disc Medicine, Inc. Director Kevin Bitterman sold 10,994 shares on October 19, 2026, for about $879,190 under a planned trading program.
- After the trade, Kevin Bitterman indirectly holds 13,312 $IRON shares, down 45.23% from before the trade.
- The stock recently traded around $79.48, sitting 20.1% below its 52-week high of $99.50 as the company prepares to report earnings on November 5, 2026.
- BMO Capital and Cantor Fitzgerald both maintained their positive ratings on October 19, 2026, lifting their price targets for the biotechnology firm.
Since the trade, $IRON is down 3.7% to date (from the $78.93 close on Oct 19, 2026).
Get Disc Medicine text alerts
We text you when insiders, Congress, analysts or big funds move on $IRON.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Disc Medicine, Inc. alert may contain errors. Disclosures
Disc Medicine, Inc. Director Kevin Bitterman sold 10,994 shares of the company on October 19, 2026. According to a Form 4 filing with the U.S. Securities and Exchange Commission, the transaction was executed at a price of $79.97 per share, for a total value of $879,190.18.
IRON
Disc Medicine, Inc.
Kevin Bitterman vs. the S&P 500
Hypothetical returns from Kevin Bitterman's disclosed trades, not real profit or advice. How we model this.
Inside Kevin Bitterman's IRON Trade
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan. Following the transaction, Bitterman directly holds 13,112 shares of the biotechnology company, representing a 45.23% reduction in his holdings. On the transaction date, Disc Medicine shares closed at $56.84.
Other Institutional Activity in Disc Medicine
Major institutional investors adjusted their positions in the company earlier in the year. Baker Bros. Advisors grew its holdings by 12,607 shares, ending with 349,657 shares worth about $25,573,912. Vestal Point Capital, LP added 850,005 shares for a 121.4% increase, holding 1,550,000 shares valued at $117,800,000 as of June 30, 2026. RA Capital Management, L.P. maintained its stake at 2,450,221 shares worth $186,216,796, while Atlas Venture Life Science Advisors, LLC held 1,513,875 shares valued at $115,054,500.
Disc Medicine, Inc. Stock Holds Steady
The stock recently traded around $79.48 as of October 21, 2026, up about 39.8% from its close on the transaction date. The shares sit 11.1% above their 50-day moving average of $71.57 and 12.5% above their 200-day moving average of $70.66. The company carries a market capitalization of roughly $2.92 billion.
Recent Earnings
Disc Medicine reported a trailing-twelve-month loss per share of $6.58. The company is scheduled to release its next financial results on November 5, 2026.
Insider Buying and Selling at Disc Medicine, Inc.
Earlier insider transactions included Chief Operating Officer Yu Jonathan Yen-Wen disposing of 9,700 shares on June 22, 2026. Chief Legal Officer Rahul Khara bought 851 shares on June 26, 2026, and later bought 1,649 shares and sold 1,649 shares on June 29, 2026, following prior coverage of the executive's trading activity.
Analysts Set New Price Targets
Wall Street firms updated their outlooks around the time of the insider trade. On October 19, 2026, BMO Capital maintained an Outperform rating while raising its price target to $120.00 from $100.00. Cantor Fitzgerald maintained an Overweight rating on the same day and lifted its price target to $170.00 from $125.00. Morgan Stanley later maintained an Overweight rating with a $92.00 price target on October 20, 2026, following prior updates from Wedbush and Wells Fargo in September. The stock currently holds a consensus recommendation of strong_buy with a mean price target of $121.00 from 10 analysts.
About Disc Medicine
Headquartered in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing treatments for serious hematologic diseases.
Bottom Line
Investors will look toward the company's upcoming earnings report on November 5, 2026, for further updates on its clinical pipeline. Future SEC filings will provide additional insight into executive and institutional ownership shifts.
Related Filing Alerts
Source: Kevin Bitterman's Form 4 filing on $IRON (Oct 19, 2026). Written by software, not financial advice. How we make alerts